drugset / Trial / NCT00705575

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension

NCT00705575

Phase 3 Completed 688 enrolled Novartis
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of 12 weeks.

Timeline

Start
2008-06
Primary completion
2009-04
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aliskiren Small molecule 300 mg
Subject Hydrochlorothiazide Unknown 25 mg